The ratings of three pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Lipocine, Inc. (LPCN) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. In Portfolio Grader’s specific subcategories of Earnings Revisions, Equity and Cash Flow, LPCN also gets an F. Shares of the stock are being traded at a very rapid pace, up 5393.3% from the week prior. To get an in-depth look at LPCN, get Portfolio Grader’s complete analysis of LPCN stock.

Alimera Sciences, Inc.’s (ALIM) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Alimera Sciences engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The stock also gets an F in Cash Flow. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. For more information, get Portfolio Grader’s complete analysis of ALIM stock.

The rating of Perrigo Co. Plc (PRGO) slips from a C to a D. The Perrigo manufactures, distributes and markets pharmaceutical and nutritional products. Shares of the stock have been changing hands at an unusually rapid pace, up 504.3% from the week prior. The trailing PE Ratio for the stock is 55.70. To get an in-depth look at PRGO, get Portfolio Grader’s complete analysis of PRGO stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.